Confluence Discovery Technologies

Executive Summary

Confluence Discovery Technologies is a full-service contract research organization (CRO) specializing in drug discovery services from idea to Investigational New Drug (IND) filing. Based in Boulder, Colorado, the company provides expert scientific support to expedite timelines and reduce costly delays in preclinical development. As a wholly owned subsidiary of Aclaris Therapeutics, Confluence leverages its parent's resources and network to serve a diverse client base in the biopharma industry. The company was founded in 2018 and operates in the pre-clinical stage, focusing on AI/ML integration and traditional drug discovery methodologies. While Confluence is a private entity with no publicly available financials, its positioning as a specialized CRO addresses a growing demand for outsourced preclinical expertise, particularly in an era of increasing R&D complexity and cost pressures. The firm's reputation for quality research and milestone-driven collaboration positions it as a reliable partner for biotech and pharmaceutical companies seeking to advance their drug candidates efficiently.

Upcoming Catalysts (preview)

• Q3 2026Announcement of new strategic partnerships or collaborations with biotech/pharma companies60% success
• Q4 2026Expansion of service capabilities or technology platform updates50% success